INT46668

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1982
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 4.61
Pain Relevance 2.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

biosynthetic process (Gpt) cytoplasm (Gpt)
Anatomy Link Frequency
liver 4
Gpt (Mus musculus)
Pain Link Frequency Relevance Heat
Paracetamol 17 99.82 Very High Very High Very High
cytokine 7 98.32 Very High Very High Very High
Inflammation 15 98.12 Very High Very High Very High
Glutamate 4 96.64 Very High Very High Very High
Analgesic 3 89.68 High High
Pain 1 84.16 Quite High
Potency 22 76.04 Quite High
antagonist 1 75.00 Quite High
fibrosis 8 72.08 Quite High
peripheral neuropathy 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hepatitis B Virus Infection 190 100.00 Very High Very High Very High
Chronic Hepatitis 62 99.54 Very High Very High Very High
Pressure And Volume Under Development 1 99.00 Very High Very High Very High
Pneumonia 1 98.12 Very High Very High Very High
Toxicity 12 96.44 Very High Very High Very High
Necrosis 2 94.72 High High
Apoptosis 30 94.56 High High
Hepatitis 86 94.48 High High
Injury 5 90.60 High High
Arthralgia 1 84.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While the PARP-activity remained essentially unchanged, the acetaminophen-induced release of both GOT and GPT from injured liver cells could be inhibited by 90-99%, when mice were injected additionally with the selective PARP-inhibitors nicotinic acid amide, benzamide, caffeine, theophyline, and thymidine, respectively.
Negative_regulation (inhibited) of Localization (release) of GPT in liver associated with paracetamol
1) Confidence 0.42 Published 1996 Journal Gen. Pharmacol. Section Abstract Doc Link 8742516 Disease Relevance 0.24 Pain Relevance 0.55
The acetaminophen-induced release of both GOT and GPT from injured liver cells could be inhibited in a dose-dependent manner, when mice were injected additionally either with increasing amounts (from (25 mg/kg to 100 mg/kg i.p.) of the PARP-inhibitor nicotinamide, with increasing amounts (from 25 mg/kg to 100 mg/kg i.p.) of the antioxidant N-acetylcysteine, or with increasing amounts (from 50 mg/kg to 300 mg/kg i.p.) of the amino acid L-methionine. 4.
Negative_regulation (inhibited) of Localization (release) of GPT in liver associated with paracetamol
2) Confidence 0.42 Published 1997 Journal Gen. Pharmacol. Section Abstract Doc Link 9013204 Disease Relevance 0.25 Pain Relevance 0.51
However, a significant inhibition (p<0.05) in the elevation of AST and ALT was observed in mice that received UBG and GIBG compared with APAP-treated mice.
Negative_regulation (inhibition) of Localization (elevation) of ALT associated with paracetamol
3) Confidence 0.41 Published 2009 Journal Chem. Biol. Interact. Section Abstract Doc Link 19109935 Disease Relevance 0.69 Pain Relevance 0.77
Decreased ALT and HBeAg clearance, however, did not seem to be related to vaccination, and the transient ALT elevations appeared to represent sporadic, acute non-A, non-B hepatitis.
Negative_regulation (Decreased) of Localization (clearance) of ALT associated with hepatitis
4) Confidence 0.11 Published 1982 Journal Ann. Intern. Med. Section Abstract Doc Link 7073149 Disease Relevance 0.73 Pain Relevance 0.08
Application of EPO significantly reduced systemic ALT release at 24 h after pHx compared to saline-treated controls (figure 4A).
Negative_regulation (reduced) of Localization (release) of ALT
5) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2592699 Disease Relevance 0.52 Pain Relevance 0.05
Secondary endpoints included the proportion of subjects with HBV DNA < 5 log copies/mL and proportion undetectable at one year, normalization of ALT, HBeAg loss, HBeAg seroconversion and therapeutic response, as defined in the GLOBE trial.
Negative_regulation (loss) of Localization (normalization) of ALT associated with hepatitis b virus infection
6) Confidence 0.03 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.58 Pain Relevance 0
In the GLOBE trial, the primary outcome was a “therapeutic response” which was defined as a decrease in the HBV DNA level to <5 log copies/mL along with either a loss of HBeAg or ALT normalization.
Negative_regulation (loss) of Localization (normalization) of ALT associated with hepatitis b virus infection
7) Confidence 0.03 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.53 Pain Relevance 0
In patients with HBeAg-negative chronic hepatitis B, PEG-IFN results in suppression of HBV DNA and ALT normalization in 36% of patients after 1 year of treatment [12].
Negative_regulation (suppression) of Localization (normalization) of ALT associated with chronic hepatitis and hepatitis b virus infection
8) Confidence 0.02 Published 2010 Journal Curr Hepat Rep Section Body Doc Link PMC2861769 Disease Relevance 0.43 Pain Relevance 0.04
Primary end point was suppression of HBV DNA levels to below 20,000 copies/mL and normalization of ALT.
Negative_regulation (suppression) of Localization (normalization) of ALT associated with hepatitis b virus infection
9) Confidence 0.02 Published 2010 Journal Curr Hepat Rep Section Body Doc Link PMC2861769 Disease Relevance 0.65 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox